Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral Therapy<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

ContextAdefovir dipivoxil is a nucleotide analog that has demonstrated effective antiretroviral activity against human immunodeficiency virus (HIV) with once-daily administration.ObjectiveTo determine if adefovir confers antiretroviral or immunologic benefit when added to stable antiretroviral therapy.DesignMulticenter, 24-week, randomized, double-blind, placebo-controlled study. Enrollment was conducted from June 3, 1996, through May 6, 1997.SettingThirty-three US HIV treatment centers.ParticipantsOf 1171 patients screened, 442 patients infected with HIV receiving stable antiretroviral therapy for at least 8 weeks with plasma HIV RNA greater than 2500 copies/mL and CD4+ cell count above 0.20 &#215; 109/L were randomized.InterventionPatients were randomized to receive either a single 120-mg/d dose of adefovir dipivoxil (n = 219) or an indistinguishable placebo (n = 223). All patients received L-carnitine, 500 mg/d. Open-label adefovir was offered after 24 weeks and was continued until the end of the study.Main Outcome MeasuresChanges in HIV RNA from baseline, based on area under the curve and CD4+ cell levels, adverse events, and effect of baseline genotypic resistance on response to adefovir.ResultsPatients assigned to adefovir demonstrated a 0.4-log10 decline from baseline in HIV RNA compared with no change in the placebo group (P